Tsunami of immunotherapy reaches mesothelioma  

作　　者：Xabier Mielgo-Rubio Ana Cardena Gutierrez Veronica Sotelo Pena Maria Virginia Sanchez Becerra Andrea Maria Gonzalez Lopez Adriana Rosero Juan Carlos Trujillo-Reyes Felipe Counago 

机构地区：[1]Department of Medical Oncology,Hospital Universitario Fundacion Alcorcon,Alcorcon 28922,Madrid,Spain [2]Department of Medical Oncology,Hospital Universitario Nuestra Senora de Candelaria,Santa Cruz de Tenerife,Canarias 38010,Spain [3]Department of Medical Oncology,Hospital Virgen de La Luz,Cuenca 16002,Spain [4]Department of Medical Oncology,Hospital Universitario Del Henares,Coslada 28822,Madrid,Spain [5]Department of Thoracic Surgery,Hospital Universitari de la Santa Creu i Sant Pau,Universitat Autonoma de Barcelona,Barcelona 08029,Spain [6]Department of Radiation Oncology,Hospital Universitario Quironsalud Madrid,Pozuelo de Alcorcon 28223,Madrid,Spain [7]Department of Radiation Oncology,Hospital La Luz,Madrid 28003,Spain [8]Medicine Department,Universidad Europea de Madrid,Villaviciosa de Odon 28670,Madrid,Spain

出　　处：《World Journal of Clinical Oncology》2022年第4期267-275,共9页世界临床肿瘤学杂志（英文版）

摘　　要：Malignant pleural mesothelioma(MPM) is the most common type of malignant mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor prognosis. Until very recently, patients with advanced or unresectable disease had limited treatment options, primarily based on doublet chemotherapy with cisplatin and pemetrexed. In 2020 and 2021, after more than a decade with no major advances or new drugs, two phase Ⅲ clinical trials published results positioning immunotherapy as a promising option for the first-and second-line treatment of MPM. Immunotherapy has revolutionized the treatment of many cancers and is also showing encouraging results in malignant mesothelioma. Both immune checkpoint inhibition and dual cytotoxic T-lymphocyte–associated antigen 4 and programmed death-ligand 1 pathway blockade resulted in significantly improved overall survival in randomized phase Ⅲ trials. In the Check Mate 743 trial, first-line therapy with nivolumab plus ipilimumab outperformed standard chemotherapy, while in the CONFIRM trial, nivolumab outperformed placebo in patients previously treated with chemotherapy. These two trials represent a major milestone in the treatment of MPM and are set to position immunotherapy as a viable alternative for treatment-naive patients and patients with progressive disease after chemotherapy.

关 键 词：MESOTHELIOMA Malignant pleural mesothelioma IMMUNOTHERAPY Immune checkpoint inhibitors Cytotoxic T-lymphocyte–associated antigen 4 Programmed cell death protein 1 Nivolumab IPILIMUMAB Immunotherapy combo Check Mate 743 CONFIRM 

分 类 号：R734.3[医药卫生—肿瘤]